Regulation of NKG2D-ligand cell surface expression by intracellular calcium after HDAC-inhibitor treatment

Molecular Immunology

Volumn 53, Issue 3, 2013, Pages 255-264

  Jensen, Helle ^a   Hagemann Jensen, Michael ^a   Lauridsen, Felicia ^a,b   Skov, Søren ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b FINSEN LABORATORY   (Denmark)

Author keywords

Calcium; Cancer; Galectin 1; HDAC inhibitor; NKG2D ligand; ULBP2

Indexed keywords

CALCIUM; CALMIDAZOLIUM; EGTAZIC ACID; GALECTIN 1; HISTONE DEACETYLASE INHIBITOR; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN MICA; PROTEIN MICB; PROTEIN ULBP2; SMALL INTERFERING RNA; TRIFLUOPERAZINE; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CONTROLLED STUDY; CYTOLYSIS; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MELANOMA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

BASE SEQUENCE; CALCIUM SIGNALING; CALMODULIN; CALPAIN; CELL LINE, TUMOR; CELL MEMBRANE; DEPSIPEPTIDES; GALECTIN 1; GENE KNOCKDOWN TECHNIQUES; GPI-LINKED PROTEINS; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMIDAZOLES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; JURKAT CELLS; LIGANDS; MELANOMA; RNA, SMALL INTERFERING; TRIFLUOPERAZINE;

EID: 84865980026     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2012.08.011     Document Type: Article

References (61)

1. Andresen L., Jensen H., Pedersen M.T., Hansen K.A., Skov S. Molecular regulation of MHC class I chain-related protein A expression after HDAC-inhibitor treatment of Jurkat T cells. Journal of Immunology 2007, 179:8235-8242.
2. Andresen L., Skovbakke S.L., Persson G., Hagemann-Jensen M., Hansen K.A., Jensen H., Skov S. 2-Deoxy d-glucose prevents cell surface expression of NKG2D ligands through Inhibition of N-linked glycosylation. Journal of Immunology 2012, 188:1847-1855.
3. Armeanu S., Bitzer M., Lauer U.M., Venturelli S., Pathil A., Krusch M., Kaiser S., Jobst J., Smirnow I., Wagner A., Steinle A., Salih H.R. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Research 2005, 65:6321-6329.
4. Barondes S.H., Castronovo V., Cooper D.N., Cummings R.D., Drickamer K., Feizi T., Gitt M.A., Hirabayashi J., Hughes C., Kasai K. Galectins: a family of animal beta-galactoside-binding lectins. Cell 1994, 76:597-598.
5. Berridge M.J., Bootman M.D., Roderick H.L. Calcium signalling: dynamics, homeostasis and remodelling. Nature Reviews Molecular Cell Biology 2003, 4:517-529.
6. Bhalla K.N. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. Journal of Clinical Oncology 2005, 23:3971-3993.
7. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nature Reviews Drug Discovery 2006, 5:769-784.
8. Camby I., Le M.M., Lefranc F., Kiss R. Galectin-1: a small protein with major functions. Glycobiology 2006, 16:137R-157R.
9. Capraru D., Muller A., Csernok E., Gross W.L., Holl-Ulrich K., Northfield J., Klenerman P., Herlyn K., Holle J., Gottschlich S., Voswinkel J., Spies T., Fagin U., Jabs W.J., Lamprecht P. Expansion of circulating NKG2D+ effector memory T-cells and expression of NKG2D-ligand MIC in granulomaous lesions in Wegener's granulomatosis. Clinical Immunology 2008, 127:144-150.
10. Champsaur M., Lanier L.L. Effect of NKG2D ligand expression on host immune responses. Immunological Reviews 2010, 235:267-285.
11. Clapham D.E. Calcium signaling. Cell 2007, 131:1047-1058.
12. Dokmanovic M., Marks P.A. Prospects: histone deacetylase inhibitors. Journal of Cellular Biochemistry 2005, 96:293-304.
13. El-Khoury V., Moussay E., Janji B., Palissot V., Aouali N., Brons N.H., Van M.K., Pierson S., Van D.E., Berchem G. The histone deacetylase inhibitor MGCD0103 induces apoptosis in B-cell chronic lymphocytic leukemia cells through a mitochondria-mediated caspase activation cascade. Molecular Cancer Therapeutics 2010, 9:1349-1360.
14. Elbein A.D. Inhibitors of the biosynthesis and processing of N-linked oligosaccharide chains. Annual Review of Biochemistry 1987, 56:497-534.
15. Fischer C., Sanchez-Ruderisch H., Welzel M., Wiedenmann B., Sakai T., Andre S., Gabius H.J., Khachigian L., Detjen K.M., Rosewicz S. Galectin-1 interacts with the {alpha}5{beta}1 fibronectin receptor to restrict carcinoma cell growth via induction of p21 and p27. Journal of Biological Chemistry 2005, 280:37266-37277.
16. Goll D.E., Thompson V.F., Li H., Wei W., Cong J. The calpain system. Physiological Reviews 2003, 83:731-801.
17. Groh V., Bruhl A., El-Gabalawy H., Nelson J.L., Spies T. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:9452-9457.
18. Groh V., Wu J., Yee C., Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002, 419:734-738.
19. Heinemann A., Zhao F., Pechlivanis S., Eberle J., Steinle A., Diederichs S., Schadendorf D., Paschen A. Tumor suppressive MicroRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D. Cancer Research 2012.
20. Himmelreich H., Mathys A., Wodnar-Filipowicz A., Kalberer C.P. Post-transcriptional regulation of ULBP1 ligand for the activating immunoreceptor NKG2D involves 3' untranslated region. Human Immunology 2011, 72:470-478.
21. Huttenlocher A., Palecek S.P., Lu Q., Zhang W., Mellgren R.L., Lauffenburger D.A., Ginsberg M.H., Horwitz A.F. Regulation of cell migration by the calcium-dependent protease calpain. Journal of Biological Chemistry 1997, 272:32719-32722.
22. Jensen H., Andresen L., Hansen K.A., Skov S. Cell-surface expression of Hsp70 on hematopoietic cancer cells after inhibition of HDAC activity. Journal of Leukocyte Biology 2009, 86:923-932.
23. Jensen H., Andresen L., Nielsen J., Christensen J.P., Skov S. Vesicular stomatitis virus infection promotes immune evasion by preventing NKG2D-ligand surface expression. PLoS ONE 2011, 6:e23023.
24. Kurtoglu M., Maher J.C., Lampidis T.J. Differential toxic mechanisms of 2-deoxy-d-glucose versus 2-fluorodeoxy-d-glucose in hypoxic and normoxic tumor cells. Antioxidants and Redox Signalling 2007, 9:1383-1390.
25. Lefranc F., Mathieu V., Kiss R. Galectin-1-mediated biochemical controls of melanoma and glioma aggressive behavior. World Journal of Biological Chemistry 2011, 2:193-201.
26. Li K., Mandai M., Hamanishi J., Matsumura N., Suzuki A., Yagi H., Yamaguchi K., Baba T., Fujii S., Konishi I. Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunology, Immunotherapy 2009, 58:641-652.
27. Louis M., Rosato R.R., Brault L., Osbild S., Battaglia E., Yang X.H., Grant S., Bagrel D. The histone deacetylase inhibitor sodium butyrate induces breast cancer cell apoptosis through diverse cytotoxic actions including glutathione depletion and oxidative stress. International Journal of Oncology 2004, 25:1701-1711.
28. Lu J., McKinsey T.A., Nicol R.L., Olson E.N. Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:4070-4075.
29. Macian F. NFAT proteins: key regulators of T-cell development and function. Nature Reviews Immunology 2005, 5:472-484.
30. Marks P.A., Dokmanovic M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opinion on Investigational Drugs 2005, 14:1497-1511.
31. Matsuda S., Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology 2000, 47:119-125.
32. McKinsey T.A., Zhang C.L., Lu J., Olson E.N. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature 2000, 408:106-111.
33. McKinsey T.A., Zhang C.L., Olson E.N. MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends in Biochemical Sciences 2002, 27:40-47.
34. Mitsiades N., Mitsiades C.S., Richardson P.G., McMullan C., Poulaki V., Fanourakis G., Schlossman R., Chauhan D., Munshi N.C., Hideshima T., Richon V.M., Marks P.A., Anderson K.C. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003, 101:4055-4062.
35. Nickel W. Unconventional secretory routes: direct protein export across the plasma membrane of mammalian cells. Traffic 2005, 6:607-614.
36. Otto H.H., Schirmeister T. Cysteine Proteases and Their Inhibitors. Chemical Reviews 1997, 97:133-172.
37. Pan F., Ye Z., Cheng L., Liu J.O. Myocyte enhancer factor 2 mediates calcium-dependent transcription of the interleukin-2 gene in T lymphocytes: a calcium signaling module that is distinct from but collaborates with the nuclear factor of activated T cells (NFAT). Journal of Biological Chemistry 2004, 279:14477-14480.
38. Paschen A., Sucker A., Hill B., Moll I., Zapatka M., Nguyen X.D., Sim G.C., Gutmann I., Hassel J., Becker J.C., Steinle A., Schadendorf D., Ugurel S. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clinical Cancer Research 2009, 15:5208-5215.
39. Perillo N.L., Pace K.E., Seilhamer J.J., Baum L.G. Apoptosis of T cells mediated by galectin-1. Nature 1995, 378:736-739.
40. Potter D.A., Tirnauer J.S., Janssen R., Croall D.E., Hughes C.N., Fiacco K.A., Mier J.W., Maki M., Herman I.M. Calpain regulates actin remodeling during cell spreading. Journal of Cell Biology 1998, 141:647-662.
41. Raffaghello L., Prigione I., Airoldi I., Camoriano M., Levreri I., Gambini C., Pende D., Steinle A., Ferrone S., Pistoia V. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 2004, 6:558-568.
42. Rao R., Nalluri S., Kolhe R., Yang Y., Fiskus W., Chen J., Ha K., Buckley K.M., Balusu R., Coothankandaswamy V., Joshi A., Atadja P., Bhalla K.N. Treatment with panobinostat induces glucose-regulated protein 78 acetylation and endoplasmic reticulum stress in breast cancer cells. Molecular Cancer Therapeutics 2010, 9:942-952.
43. Rosato R.R., Almenara J.A., Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Research 2003, 63:3637-3645.
44. Sengupta P., Ruano M.J., Tebar F., Golebiewska U., Zaitseva I., Enrich C., McLaughlin S., Villalobo A. Membrane-permeable calmodulin inhibitors (e.g. W-7/W-13) bind to membranes, changing the electrostatic surface potential: dual effect of W-13 on epidermal growth factor receptor activation. Journal of Biological Chemistry 2007, 282:8474-8486.
45. Skov S., Pedersen M.T., Andresen L., Straten P.T., Woetmann A., Odum N. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Research 2005, 65:11136-11145.
46. Song H., Kim J., Cosman D., Choi I. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression. Cellular Immunology 2006, 239:22-30.
47. Sparrow D.B., Miska E.A., Langley E., Reynaud-Deonauth S., Kotecha S., Towers N., Spohr G., Kouzarides T., Mohun T.J. MEF-2 function is modified by a novel co-repressor, MITR. The EMBO Journal 1999, 18:5085-5098.
48. Squier M.K., Miller A.C., Malkinson A.M., Cohen J.J. Calpain activation in apoptosis. Journal of Cellular Physiology 1994, 159:229-237.
49. Stillman B.N., Hsu D.K., Pang M., Brewer C.F., Johnson P., Liu F.T., Baum L.G. Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. Journal of Immunology 2006, 176:778-789.
50. Sun L., Youn H.D., Loh C., Stolow M., He W., Liu J.O. Cabin 1, a negative regulator for calcineurin signaling in T lymphocytes. Immunity 1998, 8:703-711.
51. Suzuki M., Endo M., Shinohara F., Echigo S., Rikiishi H. Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells. Cancer Chemotherapy and Pharmacology 2009, 64:1115-1122.
52. Textor S., Fiegler N., Arnold A., Porgador A., Hofmann T.G., Cerwenka A. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. Cancer Research 2011, 71:5998-6009.
53. Vales-Gomez M., Chisholm S.E., Cassady-Cain R.L., Roda-Navarro P., Reyburn H.T. Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors. Cancer Research 2008, 68:1546-1554.
54. Venkataraman G.M., Suciu D., Groh V., Boss J.M., Spies T. Promoter region architecture and transcriptional regulation of the genes for the MHC class I-related chain A and B ligands of NKG2D. Journal of Immunology 2007, 178:961-969.
55. Walzel H., Blach M., Hirabayashi J., Arata Y., Kasai K., Brock J. Galectin-induced activation of the transcription factors NFAT and AP-1 in human Jurkat T-lymphocytes. Cellular Signalling 2002, 14:861-868.
56. Walzel H., Blach M., Hirabayashi J., Kasai K.I., Brock J. Involvement of CD2 and CD3 in galectin-1 induced signaling in human Jurkat T-cells. Glycobiology 2000, 10:131-140.
57. Wei L., Lu J., Feng L., Long D., Shan J., Li S., Li Y. HIF-1alpha accumulation upregulates MICA and MICB expression on human cardiomyocytes and enhances NK cell cytotoxicity during hypoxia-reoxygenation. Life Sciences 2010, 87:111-119.
58. Yang R.Y., Rabinovich G.A., Liu F.T. Galectins: structure, function and therapeutic potential. Expert Reviews in Molecular Medicine 2008, 10:e17.
59. Youn H.D., Grozinger C.M., Liu J.O. Calcium regulates transcriptional repression of myocyte enhancer factor 2 by histone deacetylase 4. Journal of Biological Chemistry 2000, 275:22563-22567.
60. 2+-induced release of the transcription factor MEF2. Science 1999, 286:790-793.
61. Zhuo Y., Bellis S.L. Emerging role of alpha2,6-sialic acid as a negative regulator of galectin binding and function. Journal of Biological Chemistry 2011, 286:5935-5941.